ClinicalTrials.gg
CompletedNCT06772792Updated Feb 18, 2025

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)

A Phase 1 interventional study of Alendronate and Enlicitide Decanoate in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Apr 2024, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate. Researchers want to learn how safe and tolerable is the co-administration of enlicitide decanoate and alendronate.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has no medical history, physical examination, clinical laboratory profiles, vital signs, and (ECGs)
  • Has a (BMI) ≥18.0 kg/m\^2 and ≤32.0 kg/m\^2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Has a history or presence of abnormalities of the esophagus which delay emptying such as stricture or achalasia
  • Has a history of cancer ()
  • Has a history of gastrointestinal disease which may affect food and drug absorption
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Alendronate

    Participants receive a single oral dose of alendronate on Day 1 OR participants receive a single oral dose of alendronate on Day 15 depending on randomization.

    Drug: Alendronate

  • Experimental
    Alendronate + Enlicitide Decanoate

    Participants receive an oral dose of alendronate plus an oral dose of enlicitide decanoate on Day 1 OR participants receive an oral dose of alendronate plus an oral dose of enlicitide decanoate on Day 15 depending on randomization.

    Drug: Alendronate · Drug: Enlicitide Decanoate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Alendronate

    Blood samples will be collected to determine the AUC0-Last of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

  2. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Alendronate

    Blood samples will be collected to determine the AUC0-Inf of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

  3. Maximum Plasma Concentration (Cmax) of Alendronate

    Blood samples will be collected to determine the Cmax of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

  4. Time to Maximum Plasma Concentration (Tmax) of Alendronate

    Blood samples will be collected to determine the Tmax of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

  5. Apparent Terminal Half-Life (t1/2) of Alendronate

    Blood samples will be collected to determine the t1/2 of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

  6. Apparent Clearance (CL/F) of Alendronate

    Blood samples will be collected to determine the CL/F of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

  7. Apparent Volume of Distribution (Vz/F) of Alendronate

    Blood samples will be collected to determine Vz/F of alendronate.

    Time frame: At designated timepoints (up to approximately 10 hours post-dose)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 8 weeks

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 3 weeks

  3. Total Amount of Alendronate Excreted Unchanged Over a Period of 48 Hours (Ae0-48) after Alendronate Administration

    Urine samples will be collected to determine the Ae0-48 of alendronate.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose)

  4. Maximum Rate (Rmax) of Alendronate Excretion

    Urine samples will be collected to determine the Rmax of alendronate excretion.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose)

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Jun 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 14, 2025
StartActual
Apr 23, 2024
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06772792
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Apr 23, 2024
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Last update
Feb 18, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alendronate · MK-0616

Start the discussion